By: Zacks Equity Research
July 22, 2011 | Comments: 0
Recommended this article (2)
PFE | ICGN After the significant acquisitions of Wyeth and King Pharmaceuticals, Pfizer Inc. (PFE - Analyst Report) has set its aim at Icagen Inc. (ICGN - Snapshot Report) as the pharma-major inked an agreement to acquire the latter. Pfizer already owns around 11% of Icagen’s shares and will pay $6.00 per share for the remaining 89% or 8.3 million shares.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM